rs638405 — BACE1 BACE1 Exon 5 Synonymous Variant

BACE1 and the Alzheimer's Risk Variant rs638405

BACE1¹¹ BACE1
beta-site amyloid precursor protein cleaving enzyme 1 is the enzyme that makes the first cut in amyloid precursor protein (APP), initiating the amyloidogenic cascade that produces amyloid-beta peptides. Without BACE1 activity, amyloid plaques — the pathological hallmark of Alzheimer's disease — cannot form. This makes BACE1 the rate-limiting step in amyloid production and one of the most intensively studied drug targets in neurodegenerative disease.

rs638405 is a synonymous variant in exon 5: the nucleotide changes from C to G, but the encoded amino acid remains valine (GTG→GTC). It lies within the BACE1 coding sequence on chromosome 11q23.3.

The Mechanism

Because rs638405 does not change the BACE1 protein sequence, any effect it exerts must be indirect — through altered mRNA splicing²² mRNA splicing
some synonymous variants affect splice site recognition or mRNA secondary structure even without amino acid changes, differential codon usage affecting translation efficiency, or linkage disequilibrium with an unidentified nearby regulatory variant. Sjölander et al. (2010) directly tested whether rs638405 genotype affects BACE1 enzymatic activity in CSF and found no measurable difference across genotypes, arguing against a direct catalytic effect. If the SNP has a biological consequence, it is likely through gene expression regulation rather than protein function.

The Evidence

Meta-analysis by Yu et al. (2016)³³ Meta-analysis by Yu et al. (2016)
"Meta-analysis of BACE1 gene rs638405 polymorphism and the risk of Alzheimer's disease in Caucasian and Asian population." Neurosci Lett, 2016. synthesized 13 case-control studies (2,538 AD patients, 3,020 controls) and found the G-allele homozygous genotype associated with ~22% elevated AD risk (OR=1.22, 95% CI 1.04–1.44, p=0.02 for GG vs CC). Under a recessive model the OR reached 1.25 (p=0.0008). Effects were somewhat stronger in Asian populations (GG vs CC OR=1.43, p=0.01).

Jo et al. (2008)⁴⁴ Jo et al. (2008)
"Association of BACE1 gene polymorphism with Alzheimer's disease in Asian populations." Dement Geriatr Cogn Disord, 2008. identified an important subgroup effect: although the overall association was weak, among APOE4 carriers the G-allele homozygous genotype carried an OR of approximately 2.0 for Alzheimer's disease (p=0.0044). This suggests the variant may amplify the already-elevated risk conferred by APOE4.

Wang et al. (2017)⁵⁵ Wang et al. (2017)
"Relationship between the polymorphism in exon 5 of BACE1 gene and Alzheimer's disease." Aging Clin Exp Res, 2017. — the larger meta-analysis of 20 studies — found no statistically significant overall association, though it did observe a protective signal in APOE4-positive and Asian subgroups after excluding studies deviating from Hardy-Weinberg equilibrium. The lack of an overall effect across a larger sample tempers enthusiasm.

Yin et al. (2025)⁶⁶ Yin et al. (2025)
"Genetic polymorphism in beta-site amyloid precursor protein-cleaving enzyme 1 affects the structure of medial temporal lobe and cognition in AD." Eur Arch Psychiatry Clin Neurosci, 2025. found that G-allele carriers among AD patients have significantly lower global cognition and memory scores, with reduced gray matter volume in the left parahippocampus and right hippocampus — regions critical to episodic memory encoding.

Overall, the evidence suggests a modest, inconsistent association primarily detectable in Asian populations and in APOE4 carriers. The effect size is small (OR ~1.2), the mechanism is unclear, and large meta-analyses disagree. This variant is best understood as a weak modulator, not a major Alzheimer's risk gene.

Practical Actions

The modest and inconsistent risk signal from rs638405 does not support aggressive intervention on its own. However, for individuals who also carry APOE4 — where the combined signal is stronger — there is value in proactively monitoring cognitive health and protecting cerebrovascular reserve. BACE1 activity depends on cholesterol homeostasis and endosomal pH; variants in the amyloid pathway interact meaningfully with lipid metabolism genetics. Monitoring APOE status and engaging APOE-specific neuroprotective strategies (detailed in the APOE rs429358 profile) is the highest-yield action for this SNP.

For GG carriers without APOE4, the small risk increment warrants periodic cognitive screening after age 60 but not major lifestyle disruption.

Interactions

The clearest interaction is with APOE4 (rs429358, rs7412). Jo et al. (2008) showed the GG genotype is essentially neutral in APOE4-negative individuals but roughly doubles Alzheimer's risk in APOE4 carriers — a gene-gene interaction suggesting BACE1 expression and APOE lipid biology converge on amyloid clearance. The proposed mechanism is that APOE4 impairs amyloid-beta clearance while BACE1 over-activity (potentially increased by the G-allele through unknown regulatory effects) increases amyloid-beta production — creating a dual hit on amyloid homeostasis.

rs3851179 (PICALM) and rs744373 (BIN1) are endocytic pathway SNPs that affect APP trafficking and amyloid-beta production and clearance; they share the broader amyloid/endosomal pathway with BACE1.